Who are Oncovin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zithromax, Sandimmune, Oncovin, Trexall, Invirase, Vinblastin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vincristine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Oncovin — Competitive Intelligence Brief

Oncovin (vincristine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca Alkaloid. Area: Oncology.

marketed Vinca Alkaloid Canalicular multispecific organic anion transporter 1 Oncology Live · refreshed every 30 min

Target snapshot

Oncovin (vincristine) — Pfizer Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oncovin TARGET	vincristine	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Zithromax	azithromycin	Pfizer Inc.	marketed	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
Oncovin	Vincristine Sulfate	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Trexall	methotrexate	Generic (originally Lederle Laboratories)	marketed	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Invirase	Invirase	Saint Michael's Medical Center	marketed		Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1
Vinblastin	Vinblastin	The Lymphoma Academic Research Organisation	marketed		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-04 — Trexall · 8021335 · Formulation · US
2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-03-10 — Trexall · 10709844 · Formulation · US
2029-03-10 — Trexall · 9867949 · Formulation · US
2029-03-10 — Trexall · 11684723 · Formulation · US
2029-06-01 — Trexall · 8664231 · Method of Use · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-03-19 — Trexall · 8480631 · Formulation · US
2030-03-19 — Trexall · 8579865 · Formulation · US
2030-03-19 — Trexall · 12357642 · Formulation · US
2030-03-19 — Trexall · 11497753 · Formulation · US
2030-03-19 — Trexall · 9421333 · Formulation · US
2030-03-19 — Trexall · 8945063 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2031-05-27 — Trexall · 8814834 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2034-10-29 — Trexall · 11771701 · Formulation · US
2035-10-28 — Trexall · 11129833 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US

Sponsor landscape (Vinca Alkaloid class)

Pfizer Inc. · 2 drugs in this class
Pierre Fabre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oncovin — Competitive Intelligence Brief. https://druglandscape.com/ci/vincristine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab